An observational study in Shoulder Pain, sponsored by Universidad Pública de Navarra. Completed at 1 site in Spain. Open to participants aged 18 Years to 71 Years. Per ClinicalTrials.gov, last updated 2026-08-07.
Sponsored by Universidad Pública de Navarra · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 52 studies in Shoulder Pain with a site in Spain — 10 open to participants now, 10 under way, none of them phase 3. Shoulder Pain · Spain.
Among the 52 studies in Shoulder Pain with a site in Spain, this one is one of 6 that started in 2025, is one of 3 observational ones, and was the 49th registered.
738 studies on the registry are indexed under Shoulder Pain; 168 are open to participants now.
Browse Shoulder Pain studies →10 of the 52 studies in Shoulder Pain with a site in Spain are open now. Recruiting first, the newest first:
University of Alcala · Sites in Spain
Ages 18–80
University of Alcala · Sites in Spain
Ages 18–70 · Healthy volunteers
University of Seville · Sites in Spain
Ages 18+
Trak Health Solutions S.L. · Sites in Spain
Ages 18+
University of Salamanca · Sites in Spain
Ages 18–55
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 90 Shoulder Pain studies recruiting now, 25 (28%) set no upper age limit and 55 (61%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 71 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
52 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 6 started in 2025.
This study's enrollment of 159 is above the median of 84 across 135 observational studies indexed under Shoulder Pain.
Median enrollment 50 across the 49 interventional studies, 159 across the 3 observational. Of the 34 that completed or were terminated, 1 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 52 have an industry lead sponsor. The 10 most frequent:
Universidad Pública de Navarra is the lead sponsor of 14 studies on the registry; 5 are open to participants now.
Universidad Pública de Navarra has 1 study filed under Shoulder Pain — fewer than ten, so there is no comparison to draw.
4 of the studies in Shoulder Pain with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06296979University of SevilleEffectiveness of Noninvasive Phrenic Nerve Neuromodulation in Shoulder Pain and Hepatobiliary Visceral Comorbidity. | 2026-12-01 |
| NCT06398574University of AlcalaEffects of Dry Needling on the Behavior of the Shoulder Muscles | 2026-12-20 |
| NCT07637760Universidad Complutense de MadridDry Needling or Percutaneous Electrolysis for Managing Myofascial Trigger Points? | 2027-01-30 |
| NCT07621016Universidad Europea de ValenciaEffects of Dry Needling in Athletes With Subacromial Pain Syndrome | 2027-03 |
Add all 4 to your calendar (.ics) → With an account.
Among the 52 studies in Shoulder Pain with a site in Spain, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This prospective longitudinal observational cohort study compared feasibility-allocated hybrid and in-clinic rehabilitation for adults with non-traumatic shoulder pain or dysfunction managed within the same standardized web- and mobile-supported semi-automated shoulder rehabilitation system (WMSSR). The primary outcome was observed time from baseline to documented clinical discharge among completed rehabilitation episodes. Secondary outcomes included total clinical deficit score, maximum pain per visit, number of painful tests per visit, Constant-Murley score at discharge, and adherence to prescribed rehabilitation sessions.
This prospective consecutive observational study was conducted in routine outpatient care at TDN Clínica (Navarra, Spain) to assess whether outcomes differ between two physiotherapy delivery formats for adults with non-traumatic shoulder pain/dysfunction managed within the same standardized web- and mobile-supported semi-automated shoulder rehabilitation system (WMSSR) between March and September 2025 and followed within the study until 11 November 2025. Allocation to format was feasibility-based (non-random) according to routine-care constraints (e.g., work schedule, transport, distance). Both formats were delivered at a nominal frequency of three sessions/week: hybrid (1 supervised in-person session plus 2 unsupervised home sessions supported by smartphone access to prescribed exercises) and in-clinic rehabilitation (3 supervised in-clinic sessions/week).
WMSSR integrates a structured assessment-prescription-reassessment process. Patients completed a standardized 24-test functional battery at baseline (visit 1) and at follow-up evaluations scheduled every 3-5 weeks until clinical discharge. The battery includes measures of strength (digital dynamometry), range of motion (manual goniometry), flexibility, and clinical tests. Pain intensity during test performance was recorded using a 0-10 visual analogue scale (VAS). Pain-related variables included maximum pain per visit, the number of test records with VAS >0 within the 24-test assessment, and a composite VAS used to summarize episode-level pain burden and support discharge assessment. Test scoring yields a total clinical deficit score. Clinical discharge was defined within the workflow using explicit criteria (deficit score threshold, symmetric strength, functional ROM, and low pain during tests).
Study objectives:
1) To describe and compare observed time from baseline to documented clinical discharge among completed rehabilitation episodes managed with hybrid versus in-clinic rehabilitation.
(2) To describe and compare discharge total clinical deficit score and Constant-Murley score between rehabilitation modalities.
(3) To describe longitudinal changes in maximum pain and the number of painful tests across assessment visits in both rehabilitation modalities.
(4) To describe adherence to prescribed rehabilitation sessions in each rehabilitation modality.
Adults aged 18-71 years with non-traumatic shoulder pain or dysfunction persisting for more than 3 months were recruited through social media and institutional email invitations, screened for eligibility, and enrolled in routine outpatient care at TDN Clínica in Noáin, Navarra, Spain. All enrolled participants had access to a smartphone and entered the standardized WMSSR digital rehabilitation workflow. Rehabilitation modality was determined according to the practical feasibility of attending three supervised in-clinic sessions per week. The enrolled cohort comprised 159 participants contributing 164 initiated rehabilitation episodes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
One supervised in-clinic session plus two unsupervised home-based sessions per week. Clinical reassessments were performed face to face every 3-5 weeks, and the exercise prescription was updated according to the participant's clinical evolution.
Description: Three supervised in-clinic sessions per week. Clinical reassessments were performed face to face every 3-5 weeks, and the exercise prescription was updated according to the participant's clinical evolution.
Observed time to documented clinical discharge among completed rehabilitation episodes
Number of days from the baseline visit (V1) to documented clinical discharge. This outcome was analyzed among rehabilitation episodes with a documented discharge event within the predefined study window. Episodes that discontinued treatment or remained under active follow-up at database closure did not have an observed discharge outcome and were summarized separately.
Time frame: From baseline visit (V1) to documented clinical discharge, up to 200 days
Change in total clinical deficit score from baseline to discharge
The total clinical deficit score was calculated from the standardized 24-test shoulder assessment and ranged from 0 to 36 points, with higher scores indicating greater clinical impairment. Change was calculated as baseline score minus discharge score; therefore, positive values indicate a reduction in clinical deficit. The analysis included rehabilitation episodes with paired baseline and documented discharge assessments.
Time frame: Baseline visit (V1) and documented clinical discharge, up to 200 days after baseline
Maximum pain per visit during rehabilitation
Pain during test performance was recorded using a 0-10 visual analogue scale (VAS), where 0 indicates no pain and 10 indicates the greatest pain intensity. Maximum pain per visit was defined as the highest VAS value recorded across the test records completed at a given assessment visit. Values were summarized at baseline, across scheduled reassessments, and at documented clinical discharge. Lower values indicate less pain.
Time frame: At baseline, at face-to-face reassessments scheduled every 3-5 weeks, and at documented clinical discharge, up to 200 days after baseline
Number of painful tests per visit during rehabilitation
The number of painful tests per visit was defined as the count of test records with VAS \>0 within the standardized 24-test shoulder assessment. One episode-level count was calculated for each assessment visit. Values were summarized at baseline, across scheduled reassessments, and at documented clinical discharge. Lower counts indicate fewer painful responses during the assessment.
Time frame: At baseline, at face-to-face reassessments scheduled every 3-5 weeks, and at documented clinical discharge, up to 200 days after baseline
Constant-Murley score at clinical discharge
The Constant-Murley score was recorded at documented clinical discharge as an additional measure of shoulder functional status. The score ranges from 0 to 100 points, with higher values indicating better shoulder function. It was measured at discharge only and was not included among the predefined clinical discharge criteria.
Time frame: At documented clinical discharge, up to 200 days after baseline
Adherence to prescribed rehabilitation sessions
Episode-level rehabilitation adherence was calculated as the percentage of prescribed rehabilitation sessions completed during the rehabilitation episode: (number of completed prescribed sessions / total number of prescribed sessions) × 100. In the hybrid group, prescribed sessions included one supervised in-clinic session and two unsupervised home-based sessions per week. In the in-clinic group, prescribed sessions included three supervised in-clinic sessions per week. Higher percentages indicate greater adherence.
Time frame: Throughout the rehabilitation episode, from baseline until documented clinical discharge, up to 200 days
Plan to share: No — At present, there is no plan to share individual participant data (IPD). This is a single-center study with a relatively small sample and detailed clinical assessments, which may increase the risk of re-identification, and the original informed consent did not explicitly cover broad IPD sharing. De-identified summary results will be available in the published manuscript, and additional aggregated information may be considered upon reasonable request.
Ran from Mar 2025 to primary completion in Nov 2025, 7 months.
Of 49 non-industry observational studies under Shoulder Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 24. This study's 7 months is below that.
Counting every sponsor, half of 54 studies reached it within 12 months; a quarter within 4 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universidad Pública de Navarra